Entrada Therapeutics (TRDA) Income from Continuing Operations (2020 - 2026)
Entrada Therapeutics' (TRDA) quarterly Income from Continuing Operations came in at 39717000.0 in Q1 2026, down 128.93% year-on-year from 137288350.87 in Q1 2025, and down 1.39% quarter-over-quarter from 39172000.0 in Q4 2025.
Entrada Therapeutics (TRDA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 39717000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 128.93% year-over-year to 39717000.0 in Q1 2026; TTM through Mar 2026 was 166148000.0, a 771.6% decrease from a year earlier, with the FY2025 full-year figure at 143726000.0, down 319.01% from the prior year.
- Income from Continuing Operations retreated to 39717000.0 in Q1 2026 per TRDA's latest filing, from 39172000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 54989000.0 in Q2 2024 and bottomed at 44134000.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 21671000.0 (2022), against an average of 12892411.76.
- Across the five-year window, Income from Continuing Operations soared 452.05% in 2024 and sank 3563.48% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 24629000.0 in 2022, then soared by 61.42% to 9503000.0 in 2023, then soared by 111.9% to 1131000.0 in 2024, then sank by 3563.48% to 39172000.0 in 2025, then fell by 1.39% to 39717000.0 in 2026.
- Per Business Quant, the three latest TRDA Income from Continuing Operations figures stand at 39717000.0 (Q1 2026), 39172000.0 (Q4 2025), and 44134000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Entrada Therapeutics | 245.16 Mn | 245.16 Mn | - | -39.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.72 Mn |
| Dec 31, 2025 | -39.17 Mn |
| Sep 30, 2025 | -44.13 Mn |
| Jun 30, 2025 | -43.13 Mn |
| Mar 31, 2025 | -17.35 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | -14.03 Mn |
| Jun 30, 2024 | 54.99 Mn |
| Mar 31, 2024 | 23.50 Mn |
| Dec 31, 2023 | -9.50 Mn |
| Sep 30, 2023 | 35.46 Mn |
| Jun 30, 2023 | -25.93 Mn |
| Mar 31, 2023 | -6.67 Mn |
| Dec 31, 2022 | -24.63 Mn |
| Sep 30, 2022 | -25.14 Mn |
| Jun 30, 2022 | -23.18 Mn |
| Mar 31, 2022 | -21.67 Mn |
| Dec 31, 2021 | -47.36 Mn |
| Sep 30, 2021 | -34.46 Mn |
| Jun 30, 2021 | -9.90 Mn |